CD274 and non-small cell lung carcinoma: This study investigated the efficacy, safety, and cost‐effectiveness of PD‐1/PD‐L1 inhibitors as a first‐line treatment for advanced or metastatic NSCLC with high‐level PD‐L1 expression.